Evotec (EVO) vs Tilray Brands (TLRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evotec (EVO) has outperformed Tilray Brands (TLRY) over the past year, losing 58.9% versus a loss of 78.3%. Over five years, EVO leads with a -92.9% price change compared with -96.4% for TLRY. Evotec is the larger company by market cap ($572.2 million vs $549.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVO | TLRY |
|---|---|---|
| Share price | $1.61 | $3.72 |
| Market cap | $572.18M | $549.01M |
| 1-day change | -1.23% | -1.72% |
| YTD return | -47.73% | -58.86% |
| 1-year return | -58.93% | -78.27% |
| 5-year return | -92.87% | -96.37% |
| Forward P/E | — | 20.92 |
| EPS (TTM) | $-0.64 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.27 | $23.20 |
| 52-week low | $1.50 | $3.54 |
| Distance from 52-week high | -62.30% | -83.99% |
| Analyst consensus | none | buy |
| Avg. price target upside | +158.39% | +92.73% |
| Average volume | 104.15K | 4.08M |
| Shares outstanding | 355.39M | 147.78M |
| Employees | 4,461 | 3,595 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EVO has outperformed TLRY by 19.3 percentage points over the past year.
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Healthcare · Drug Manufacturers - Specialty & Generic · 4,461 employees
About Tilray Brands
TLRY stock →Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness.
Healthcare · Drug Manufacturers - Specialty & Generic · 3,595 employees
EVO vs TLRY FAQ
Which is bigger, Evotec or Tilray Brands?
Evotec (EVO) is larger, with a market capitalization of $572.18M compared with $549.01M for Tilray Brands (TLRY).
Which stock has performed better over the past year, EVO or TLRY?
EVO returned -58.93% over the past 12 months, compared with -78.27% for TLRY (price return, excluding dividends). Past performance does not predict future results.
Are Evotec and Tilray Brands in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.